Arc Bio Team
Chief Executive Officer
Todd Dickinson has been the CEO of Arc Bio and Dovetail Genomics since February 2015. He is a founding scientist of Illumina and has held numerous technical and commercial executive roles both at Illumina and subsequently at BioNano Genomics.
David Pryor, MD
Chief Medical Officer
David Pryor joined the leadership team in 2020. David has over 35 years’ experience as a distinguished health care leader, most recently as the former Executive VP and Chief Clinical Officer of Ascension Health. He has served on many national and international committees, authored over 250 publications, and has been recognized as being among the most influential leaders and physicians in health care.
Vice President, Commercial Operations
Naissan Hussainzada has >15 years of experience in the pharmaceutical and biotech industry experience across therapeutic sectors including CNS disorders, GI disorders, infectious disease, clinical toxicology and molecular diagnostics.
Vice President, Research and Development
Manuel Krispin has over 14 years of experience in development of NGS and Real-Time PCR molecular diagnostic tests in the biotech industry. He received his PhD in Epigenetics from the Saarland University, Germany and has extensive technical expertise in diverse areas including Molecular Biology, Oncology and Biochemistry.
Matt has served as the General Counsel for Arc Bio since its formation. Matt graduated magna cum laude from University of Minnesota law school and has a PhD in neuroscience. Previously, Matt was a patent attorney with WSGR in Palo Alto where he worked on IP strategy for early stage biotech companies. Matt conducted his doctoral research at the UCLA and postdoctoral fellowships at the Children’s Hospital of Philadelphia and the University of Minnesota.
Professor Carlos Bustamante is an internationally recognized leader in data science and genomics technologies. He is currently Professor of Biomedical Data Science, Genetics and Biology at Stanford University.
Professor David Sinclair is at the department of Genetics and co-Director of the Paul Glenn Center for the Biology of Aging at Harvard Medical School. Time magazine recently named him on their list ”100 most influential people in the world”.
Director, Assay Development
Meredith Carpenter has been with Arc Bio since its inception. She has a PhD in Molecular and Cell Biology from UC Berkeley, and she completed her postdoctoral work in the Genetics Department at Stanford where she developed methods for analyzing ancient DNA. Dr. Carpenter has broad expertise in genomics, particularly in the areas of ancient/degraded DNA and clinical sample methods development.
Director, Clinical Deployment
Gavin Wall is a clinical microbiologist with 18 years of international experience in both diagnostic microbiology and the in vitro diagnostics industry. He studied Microbiology and Virology at the University of Warwick, UK before being accepted to a 4-year national training programme and received his UK state registration as a Clinical Scientist in 2008. He acted as Lead Clinical Scientist in the department of Clinical Virology at Barts and The London NHS Trust before joining QIAGEN in 2011 where he most recently worked as global lead of Medical and Scientific Affairs, Infectious Diseases.
Thomas Watson has been with Arc Bio since its inception. He has a PhD in Quantum Chemistry from the University of Florida and completed post-doctoral work at Princeton. Expertise spanning all areas of computational biology.
Scientific Advisory Board
David Relman, MD
Thomas C. and Joan M. Merigan Professor in Medicine, and Microbiology & Immunology, and Co-Director of the Center for International Security and Cooperation at Stanford University
Dr. Relman is Chief of Infectious Diseases at the Veterans Affairs Palo Alto Health Care System in Palo Alto, California. His research focus is the human indigenous microbiota, and the identification of previously-unrecognized microbial agents of disease. He has advised the U.S. Government on emerging infectious diseases, human-microbe interactions, and future biological threats.
Ami Bhatt, MD, PhD
Assistant Professor of Medicine (Hematology) and Genetics at Stanford University
Dr. Bhatt’s group works to identify problems and questions that arise in the course of routine clinical care through the use of modern genetic, molecular and computational techniques. She seeks to exhaustively characterize the dynamics of the microbiota and environmental pathogens in immunocompromised and underserved populations and to explore how changes in the microbiome are associated with diseases in these populations.
Beth Shapiro, PhD
Associate Professor in the Department of Ecology & Evolutionary Biology at UC Santa Cruz
Dr. Shapiro’s research aims to better understand how populations and species change through time, particularly in response to environmental and other changes to their habitat using the latest experimental and computational approaches to analyze genetic information isolated from fossil and archived remains. She was selected as a MacArthur fellow in 2009.
Chris Mason, PhD
Associate Professor at Weill Cornell Medicine
Dr. Mason’s lab uses high-throughput sequencing-based methods to generate cell-specific molecular maps of genetic, epigenetic, and transcriptional activity, which give multi-dimensional molecular portraits of development and disease. They then develop algorithms to leverage these data for detecting, cataloging and functionally annotating interactions between these molecular changes and also connect them to larger datasets (ENCODE, TCGA, ICGC) for replication and contextualization.
Dan Rokshar, PhD
Professor of Genetics, Genomics and Development at the University of California at Berkley
Dr. Rokhsar’s research is focused on understanding the origin, evolution, and diversity of animals (and, more generally, other groups of eukaryotes) by combining computational genome analysis with comparative developmental biology. He is a specialist in de novo genome assembly.
Richard "Ed" Green, PhD
Assistant Professor in the Department of Biomolecular Engineering at UC Santa Cruz
Dr. Green led the project to sequence the first Neandertal genome in 2008, and he has extensive expertise in genomics and computational molecular biology. He is also President of Dovetail Genomics, a company that has commercialized Dr. Green’s work developing an in vitro method for constructing mate-pair libraries whose inserts span all distances up to the size of the input DNA.
Yaniv Erlich, PhD
Assistant Professor of Computer Science and Computational Biology at Columbia University
Dr. Erlich is a core member at the New York Genome Center and is currently CSO of MyHeritage. Dr. Erlich’s research interests revolve around computational human genetics.
An avid inventor experienced R&D leader, a biotech executive, entrepreneur, and active member of his community. Bob retired from Illumina in 2014 after 14 years as Chief Engineering Officer. Prior to joining Illumina, Bob was the Director of the Microarray Business Unit at Molecular Dynamics.